Evotec SE increased revenue and expanded its drug discovery and development alliances in the first half of 2022 even as some sectors of the pharma industry experienced a slowdown. Group revenue was €336.9 million, up by 24% from a year earlier. More than three quarters of group revenue, or €258.8 million, was generated by the company’s fee-for-service business while €78 million came from partnered drug discovery.
